Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Accumulated Expenses: 2011-2024

Historic Accumulated Expenses for Amicus Therapeutics (FOLD) over the last 12 years, with Dec 2024 value amounting to $127.3 million.

  • Amicus Therapeutics' Accumulated Expenses rose 25.75% to $171.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $171.2 million, marking a year-over-year increase of 25.75%. This contributed to the annual value of $127.3 million for FY2024, which is 11.75% down from last year.
  • As of FY2024, Amicus Therapeutics' Accumulated Expenses stood at $127.3 million, which was down 11.75% from $144.2 million recorded in FY2023.
  • Over the past 5 years, Amicus Therapeutics' Accumulated Expenses peaked at $144.2 million during FY2023, and registered a low of $93.6 million during FY2022.
  • Its 3-year average for Accumulated Expenses is $121.7 million, with a median of $127.3 million in 2024.
  • Per our database at Business Quant, Amicus Therapeutics' Accumulated Expenses skyrocketed by 54.05% in 2023 and then decreased by 11.75% in 2024.
  • Over the past 5 years, Amicus Therapeutics' Accumulated Expenses (Yearly) stood at $96.8 million in 2020, then grew by 1.35% to $98.2 million in 2021, then dropped by 4.60% to $93.6 million in 2022, then soared by 54.05% to $144.2 million in 2023, then dropped by 11.75% to $127.3 million in 2024.